Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecnoglutide for Obesity with Knee Osteoarthritis (Phase III)
ChiCTR2600128053Phase 3Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and knee osteoarthritis (OA) comparing Ecnoglutide injection with Placebo injection (2 arms). Primary endpoints: Body weight (primary) and WOMAC Pain Subscale Score (primary). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ecnoglutide
03
Conditions
obesityknee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2600128053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128053.